GaoTian Bio, a Pioneer in Lipid Nanomedicines, Completes Over RMB 100 Million Series B Financing
Hangzhou Gaotian Biopharmaceutical Co., Ltd. is dedicated to developing innovative lipid nanoparticle-based drugs for the treatment of cancer, autoimmune diseases, and metabolic disorders. VCBeat has learned that Gaotian Biopharma recently completed a Series B financing round exceeding RMB 100 million. The round was led by Chenyi Investment, with participation from existing shareholder Tigermed through its industrial fund Taikun Fund, as well as Hangzhou State-owned Capital Investment Group, Haihui Investment, Minsheng Pharmaceutical, and other investors.
The funds raised in this offering will be used to advance the clinical development of Gaotian’s oncology pipeline and to submit clinical trial applications for the Company’s mRNA-LNP projects.
Gaotian Biotech possesses leading lipid-based nanomedicine formulation technologies, encompassing three major lipid technology platforms: small-molecule liposomes, antibody-conjugated liposomes (including lipid ADCs and lipid bispecific antibodies), and nucleic acid lipid nanoparticles (siRNA/mRNA-LNPs). The company is developing multiple small-molecule liposome and antibody-conjugated liposome drugs for solid tumor indications, with one pipeline having entered Phase I clinical trials in both China and the United States, one pipeline at the stage of clinical trial application in both countries, and several pipelines in preclinical development. Meanwhile, the company is also developing multiple long-acting protein replacement therapies based on mRNA-LNP technology.
Professor Xu Yuhong, founder of Gaotian Biologics, stated: “The emergency approval of mRNA vaccines has once again brought lipid nanoparticle technology into the public spotlight. Cationic liposomal LNPs are a technology we have been researching for many years and represent the most mature non-viral vector solution for nucleic acid drug delivery currently available. We have long anticipated more clinical LNP application cases to guide formulation optimization and new product development.”
“The success of this mRNA vaccine has significantly bolstered our confidence in our own pipeline. Like other liposomal drugs, LNPs are inherently complex injectables, posing high barriers to industrial-scale manufacturing. With 30 years of deep expertise in this field, we have mastered the foundational technologies of lipid-based nanomedicines and established GMP-compliant mass production capabilities. We thank our investors for their trust and support. We firmly believe that quality originates from design—‘Quality by Design.’ Our profound understanding of lipid carrier technology enables us to develop new drugs and therapies with enhanced efficacy and greater cost-effectiveness, while minimizing risk.”
Gaotian Biopharma is a leading innovative pharmaceutical R&D and manufacturing company specializing in the development of lipid-based drugs. Gaotian Biopharma’s proprietary pipeline covers small molecules, antibodies, and gene therapy drugs, and the company has established an integrated platform supporting the R&D of novel lipid-based therapeutics, encompassing preclinical evaluation, process development, translational research, clinical development, and manufacturing. It also possesses a complete system for the R&D, production, and quality control of LNP formulations. Currently, the company operates a 3,000-square-meter R&D center and a cGMP-compliant production facility for complex injectables at the Binjiang Minsheng Pharmaceutical Industrial Park. In addition to supporting the R&D and production of its own pipeline, Gaotian Biopharma assists numerous partners in the cell and gene therapy sectors with process development and optimization of LNP formulations, as well as the production of clinical samples.
Founded by Ms. Liu Xiaodan in 2019, Chenyi Investment manages assets exceeding RMB 10 billion. The firm focuses on three key sectors—Healthcare and Health, Consumer and Services, and Technology and Manufacturing—with a specialization in growth-stage and late-stage mergers, acquisitions, and consolidation opportunities. Its core team comprises seasoned professionals from top-tier international and domestic investment banks, as well as renowned private equity (PE) and venture capital (VC) firms both within and outside China. Each member boasts over a decade of experience in cross-border, multi-currency, and multi-product investment banking and investment activities. Adhering to the investment philosophy that “research discovers value, and transactions create opportunities,” Chenyi Investment leverages its in-depth industry analysis and profound understanding of capital markets. By focusing on industries undergoing structural transformation and innovative growth, the firm provides long-term support to high-potential enterprises, thereby creating sustained value for investors and society.
Taikun Fund is a biomedical industry fund jointly established by Tigermed, Hangzhou Capital, and Hanggao Sci-Tech Innovation. Leveraging Tigermed’s industrial layout in clinical CRO services and aligning with the development strategy of Hangzhou’s pharmaceutical industry, the fund operates on a market-oriented basis. Focusing on the life and health industry, it primarily invests in enterprises engaged in innovative medical devices, biopharmaceuticals, healthcare services, healthcare informatization, digital therapeutics, intelligent manufacturing, and nutritional health.
Hangzhou Jintou Industry is a professional investment platform under Hangzhou Financial Investment Group, responsible for industrial investment and financing operations, with assets under management nearing RMB 10 billion. The company focuses on key real-economy sectors such as hard technology, advanced manufacturing, the information economy, healthcare, new materials, and new energy. By leveraging diverse instruments—including fund of funds, equity funds, specialized funds, mezzanine investments, M&A funds, and investment advisory services—it provides comprehensive financial solutions to leading enterprises and listed companies in the real economy.